2022 World Conference on Lung Cancer (ePosters)-EP08.02-161. An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer

EP08.02-161. An Exploratory Study on Biomarkers Related to Primary Resistance Of EGFR-TKIs Therapy in Lung Cancer

Pdf Summary

This study examined potential biomarkers related to primary resistance of EGFR-TKIs therapy in lung cancer. EGFR-TKIs have improved prognosis in non-small cell lung cancer patients with EGFR mutations, but a significant percentage of patients have a poor response, indicating primary or intrinsic resistance. Next generation sequencing and PD-L1 expression tests were performed on tumor tissues and blood samples of enrolled patients. The study included 74 patients, 49 in the primary resistance group and 25 in the sensitive group. Biomarkers of primary resistance previously reported were primary T790M mutation, PIK3CA mutation, KRAS mutation, CDK6 mutation, PTEN deletion, and MET amplification. Additionally, novel mutations potentially related to primary resistance were found. Unique signal pathways enriched in the primary resistance group were the PIK3CA/Akt/mTOR signal pathway, VEGF pathway, Apelin signaling pathway, AMPK signaling pathway, and Wnt signaling pathway. Higher expression of PD-L1 was significantly associated with shorter overall survival and progression-free survival. The positive expression of PD-L1 was higher in the primary resistance group compared to the sensitive group. The study concluded that mutations affecting the function of tumor cells and activation of specific signaling pathways may be related to primary resistance of EGFR-TKIs, and that PD-L1 expression may also play a role in this resistance.

Asset Subtitle

Lin Wu

Meta Tag

Speaker Lin Wu

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

biomarkers

EGFR-TKIs

primary resistance

lung cancer

EGFR mutations

PD-L1 expression

T790M mutation

PIK3CA mutation

KRAS mutation

signal pathways